Back to search

Article

EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progress

2020-05-18

Abstract excerpt

<title>Abstract</title> <p><bold>BACKGROUND: </bold>Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer that lacks expression of estrogen receptor (ER) and progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) gene. Chemotherapy remains the standard of care for TNBC treatment, but considerable patients are very resistant to chemotherapy. Mutations or a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2a5c7070-cad4-5d0e-9d4d-cd673ab40618
DOI
10.21203/rs.3.rs-16904/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
EZH2 inhibitors-mediated epigenetic reactivation of FOSB inhibits triple-negative breast cancer progressDOI 10.21203/rs.3.rs-16904/v2
Select a neighboring publication to make it the new centre.